Spinal and cutaneous schwannomatosis is a variant form of type 2 neurofibromatosis: A clinical and molecular study

被引:61
|
作者
Evans, DGR
Mason, S
Huson, SM
Ponder, M
Harding, AE
Strachan, T
机构
[1] UNIV OXFORD,RADCLIFFE HOSP TRUST,DEPT CLIN GENET,OXFORD OX3 7LJ,ENGLAND
[2] ADDENBROOKES HOSP,CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 2QQ,ENGLAND
[3] UNIV NEWCASTLE UPON TYNE,DIV HUMAN GENET,NEWCASTLE TYNE NE2 4AA,TYNE & WEAR,ENGLAND
[4] INST NEUROL,NEUROGENET SECT,LONDON WC1N 3BG,ENGLAND
来源
关键词
neurofibromatosis; schwannomatosis; schwannoma; meningioma; spinal tumour; DINUCLEOTIDE REPEAT POLYMORPHISM; GENETIC-LINKAGE; UNITED-KINGDOM; NF2; GENE; NEURILEMMOMATOSIS; LOCUS;
D O I
10.1136/jnnp.62.4.361
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective - To delineate the clinical phenotype, molecular basis, and implications for screening in patients and families with multiple schwannomas not generally involving the cranium. Methods - As part of a United Kingdom clinical and genetic study of type 2 neurofibromatosis (NF2) patients and families with multiple schwannomas who do not fulfil diagnostic criteria for NF2 have been identified. The clinical phenotype was studied in the extended families and molecular analysis was carried out at the NF2 gene locus on chromosome 22. Results - Patterns of inheritance in five families with schwannomatosis are consistent with inheritance of an autosomal dominant gene. The consistency of phenotype, with relative sparing of the cranium, is constant in these families. However, families which initially seem to be indicative of schwannomatosis may develop into classic NF2 as shown by a sixth family. Many of the tumours found in these families were referred to as ''neurofibroma'' when they were clearly schwannomas. This difference in classification has major implications for the relative risk of each particular type of neurofibromatosis and neuropathological review may be important in some cases. Genetic linkage analysis in the two largest families is entirely consistent with primary involvement of the NF2 gene. Conclusions - Variant forms of neurofibromatosis have presented a dilemma in classification and determination of recurrence risks in families. Previous reports have suggested that schwannomatosis is a sporadic non-hereditary condition. Patients with multiple schwannomas are likely to have a variant form of NF2 and up to a 50% risk of passing on a gene predisposing to multiple schwannoma.
引用
收藏
页码:361 / 366
页数:6
相关论文
共 50 条
  • [21] BEVACIZUMAB: AN EFFECTIVE TREATMENT FOR SPINAL AND PERIPHERAL NERVE SCHWANNOMAS ASSOCIATED WITH NEUROFIBROMATOSIS TYPE II AND SCHWANNOMATOSIS
    Henry, Joshua
    Bala, Arul
    Freeman, Simon
    King, Andrew
    Rutherford, Scott
    Mills, Samantha
    Huson, Susan
    McBain, Catherine
    Lloyd, Simon
    Evans, Gareth
    McCabe, Martin
    NEURO-ONCOLOGY, 2012, 14 : 19 - 19
  • [22] Spinal Neurofibromatosis (SNF): A Variant Phenotype of Neurofibromatosis Type 1 (NF1)
    Rogawski, David S.
    Tong, Elizabeth
    Campen, Cynthia
    JOURNAL OF PEDIATRICS, 2023, 261
  • [23] Schwannomatosis/neurofibromatosis type 2 associated visualized on FDG-PET/CT
    Beylergil, V.
    Haque, S.
    Carver, A.
    Bilsky, M. H.
    Carrasquillo, J. A.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2013, 32 (04): : 275 - 276
  • [24] Neurofibromatosis type 2 in the elderly population: Clinical and molecular features
    Goutagny, Stephane
    Bah, Alpha B.
    Parfait, Beatrice
    Sterkers, Olivier
    Kalamarides, Michel
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2013, 161A (04) : 667 - 670
  • [25] Neurofibromatosis type 2 (NF2): A clinical and molecular review
    DGareth R Evans
    Orphanet Journal of Rare Diseases, 4
  • [26] Neurofibromatosis type 2 (NF2): A clinical and molecular review
    Evans, D. Gareth R.
    ORPHANET JOURNAL OF RARE DISEASES, 2009, 4
  • [27] A CLINICAL-STUDY OF TYPE-2 NEUROFIBROMATOSIS
    EVANS, DGR
    NEARY, W
    HUSON, S
    NEWTON, V
    DONNAI, D
    HARRIS, R
    AMERICAN JOURNAL OF HUMAN GENETICS, 1991, 49 (04) : 46 - 46
  • [28] Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation
    Plotkin, Scott R.
    Messiaen, Ludwine
    Legius, Eric
    Pancza, Patrice
    Avery, Robert A.
    Blakeley, Jaishri O.
    Babovic-Vuksanovic, Dusica
    Ferner, Rosalie
    Fisher, Michael J.
    Friedman, Jan M.
    Giovannini, Marco
    Gutmann, David H.
    Hanemann, Clemens Oliver
    Kalamarides, Michel
    Kehrer-Sawatzki, Hildegard
    Korf, Bruce R.
    Mautner, Victor-Felix
    MacCollin, Mia
    Papi, Laura
    Rauen, Katherine A.
    Riccardi, Vincent
    Schorry, Elizabeth
    Smith, Miriam J.
    Stemmer-Rachamimov, Anat
    Stevenson, David A.
    Ullrich, Nicole J.
    Viskochil, David
    Wimmer, Katharina
    Yohay, Kaleb
    Huson, Susan M.
    Wolkenstein, Pierre
    Evans, D. Gareth
    GENETICS IN MEDICINE, 2022, 24 (09) : 1967 - 1977
  • [29] A clinical study of vestibular schwannomas in type 2 neurofibromatosis
    Kishore, A
    O'Reilly, BF
    CLINICAL OTOLARYNGOLOGY, 2000, 25 (06) : 561 - 565
  • [30] PHASE II STUDY OF AXITINIB IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2-RELATED SCHWANNOMATOSIS AND PROGRESSIVE VESTIBULAR SCHWANNOMAS
    Garcia, Mekka R.
    Hagiwara, Mari
    Yaffe, Anna
    Mitchell, Carole
    Akshintala, Srivandana
    Nicolaides, Theodore
    Phadnis, Sheetal S.
    Yohay, Kaleb
    Feng, Yang
    Goldberg, Judith D.
    Allen, Jeffrey C.
    Karajannis, Matthias A.
    NEURO-ONCOLOGY, 2024, 26